SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Bailey K Thomas (Last) (First) (Middle) 5025 PULLMAN AVE NE (Street) SEATTLE WA 98105 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/31/2008	3. Issuer Name and Ticker or Trading Symbol ANGIOTECH PHARMACEUTICALS INC [ ANPI ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Awards	(1)	01/21/2009	Common Stock	75,000	$31.85	D
Awards	(2)	06/09/2009	Common Stock	15,000	$27.75	D
Awards	(3)	12/01/2010	Common Stock	50,000	$17.41	D
Awards	(4)	01/26/2010	Common Stock	60,000	$18	D
Awards	(5)	02/01/2012	Common Stock	200,000	$7.65	D

Explanation of Responses:

1. The option is currently exercisable as to all 75000 shares. The option became exercisable on 12/1/2003 having vested in 48 equal installments over four years with the last installment vesting on 12/1/2007.

2. The option is currently exercisable as to 14063 shares. The option became exercisable on 7/1/2004 and will continue to vest with respect to the remaining 937 shares in equal installments on a monthly basis until 6/1/2008.

3. The option is currently exercisable as to 28125 shares. The option became exercisable on 1/1/2006 and will continue to vest with respect to the remaining 21,875 shares in equal installments on a monthly basis until 12/1/2009.

4. The option is currently exercisable as to 47500 shares. The option became exercisable on 2/1/2005 and will continue to vest with respect to the remaining 12,500 shares in equal installments on a monthly basis until 1/1/2009.

5. The option is currently exercisable as to 54167 shares. The option became exercisable on 3/1/2007 and will continue to vest with respect to the remaining 145,833 shares in equal installments on a monthly basis until 2/1/2011.

Remarks:

(1), (2) & (3) Conversions or Exercise Prices are listed in Canadian Funds. (4) & (5) Conversion or Exercise Price amounts are in US funds.

	/s/ K. Thomas Bailey	04/10/2008
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.